Elevated homocysteine level related to poor outcome after thrombolysis in acute ischemic stroke

Medical Science Monitor

Volumn 22, Issue , 2016, Pages 3268-3273

  Yao, En Sheng ^a,b   Tang, Yan ^c   Xie, Min Jiexie ^a   Wang, Ming Huan ^a   Wang, Hong ^b   Luo, Xiang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b First Affiliated Hospital   (China)

^c SHIHEZI UNIVERSITY   (China)

Author keywords

Homocysteine; Patient outcome assessment; Stroke; Thrombolytic therapy

Indexed keywords

ALTEPLASE; HOMOCYSTEINE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD BIOCHEMISTRY; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; HUMAN TISSUE; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK FACTOR; TREATMENT OUTCOME; AGED; BLOOD; COHORT ANALYSIS; DIAGNOSTIC IMAGING; MIDDLE AGED; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STROKE;

AGED; COHORT STUDIES; FEMALE; HOMOCYSTEINE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84988892478     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.900010     Document Type: Article

References (17)

1. Sun H, Zou X, Liu L: Epidemiological factors of stroke: a survey of the current status in china. J Stroke, 2013; 15: 109–14
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med, 1995; 333: 1581–87
3. Hacke W, Kaste M, Bluhmki E et al: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med, 2008; 359: 1317–29
4. Lees KR, Bluhmki E, von Kummer R et al: Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet, 2010; 375: 1695–703
5. Zhong C, Lv L, Liu C et al: High homocysteine and blood pressure related to poor outcome of acute ischemia stroke in Chinese population. PLoS One, 2014; 9: e107498
6. Kwon HM, Lee YS, Bae HJ, Kang DW: Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke. Stroke, 2014; 45: 871–73
7. Shi Z, Guan Y, Huo YR et al: Elevated total homocysteine levels in acute ischemic stroke are associated with long-term mortality. Stroke, 2015; 46: 2419–25
8. Adeoye O, Hornung R, Khatri P, Kleindorfer D: Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: A doubling of treatment rates over the course of 5 years. Stroke, 2011; 42: 1952–55
9. Zhou F, Chen B, Chen C et al: Elevated homocysteine levels contribute to larger hematoma volume in patients with intracerebral hemorrhage. J Stroke Cerebrovasc Dis, 2015; 24: 784–88
10. Mach F, Schönbeck U, Bonnefoy JY et al: Activation of monocyte/macro-phage functions related to acute atheroma complication by ligation of CD40 induction of collagenase, stromelysin, and tissue factor. Circulation, 1997; 96: 396–99
11. Rosell A, Ortega-Aznar A, Alvarez-Sabín J et al: Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke, 2006; 37: 1399–406
12. Ribo M, Montaner J, Molina CA et al: Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke, 2004; 35: 2123–27
13. Tu WJ, Zhao SJ, Liu TG et al: Combination of high-sensitivity C-reactive protein and homocysteine predicts the short-term outcomes of Chinese patients with acute ischemic stroke. Neurol Res, 2013; 35: 912–21
14. Gong X, Zou X, Liu L et al: Prognostic value of inflammatory mediators in 1-year outcome of acute ischemic stroke with middle cerebral artery stenosis. Mediators Inflamm, 2013; 2013: 850714
15. Toole JF, Malinow MR, Chambless LE et al: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA, 2004; 291: 565–75
16. Ji Y, Song B, Xu Y et al: Prognostic Significance of Homocysteine Levels in Acute Ischemic Stroke: A Prospective Cohort Study. Curr Neurovasc Res, 2015; 12: 334–40
17. He Y, Li Y, Chen Y, Feng L, Nie Z: Homocysteine level and risk of different stroke types: A meta-analysis of prospective observational studies. Nutr Metab Cardiovasc Dis, 2014; 24: 1158–65